Research in Dermatology

In addition to dermatology faculty who conduct research, most residents have participated in clinical research and other scholarly projects such as preparing case reports, reviewing articles and developing Internet-based teaching materials. In fact, the ACGME Residency Review Committee commended our program on resident participation in research

Opportunities to conduct basic science research exist within the division of dermatology and medical school. A combined residency/postdoctoral fellowship program that consists of 2 years of clinical training and 2 years of basic science research is an option for interested and appropriate candidates. Please contact the program director for additional information.

Current Research Projects

Targeting the IFN-γ-chemokine axis for treatment of vitiligo

Tracking “real-time” autoreactive T cell migration and interactions within the skin

Developing a “humanized” mouse model of immune-skin interactions to serve as a pre-clinical bridge to clinical studies

Clinical trial to test a novel treatment for vitiligo

A Phase 3 study of 2 dose regimens of telaprevir in combination with Peginterferon Alfa 2a (Pegasys) and Ribavirin (Copegus) in treatment naïve subjects with Genotype I chronic Hepatitis C.

A Survery Study on Lifestyle in Acne Vulgaris Patients.

A randomized double-blind, placebo-controlled Phase III trial of telaprevir with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) in subjects with Genotype I chronic Hepatitis C infection who did not achieve sustained virologic response following prior treatment with pegylated interferon plus ribavirin.

Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an epidemiologic analysis.

The Utility of Complete Skin Examinations.

Phase II DBPCT of the safety and efficacy of thymosin beta 4 in the treatment of patients with junctional or dystrophic epidermolysis bullosa. 

Perioral Dermatitis Survey Study. 

Exploring epigenetic markers in neurons grown from reprogrammed skin cells. 

Novartis Protocol CFTY720D2309 Study of Fingolomid for Multiple Sclerosis.